---
Overview
How psychedelic-assisted therapy works
Existing addiction medicines target drug receptors in the brain, to reduce symptoms such as cravings. These have low long-term success rates for substance addiction, and offer no solution to behavioural addiction.
Our approach is different, delivering profound and long lasting changes over a single course of treatment.
Addiction – like anxiety, depression, and PTSD – is based on patterns of behaviour established in the brain, usually in response to trauma.
Our psychedelics disrupt the brain circuits that underlie these unhelpful patterns. They weaken neural connections linked to harmful thought patterns, opening the door for clients to rewrite constructive alternatives. By focusing on circuit mechanisms, not receptors, our approach has potential to work in behavioural addictions such as gambling, and for mental health conditions.
Through inducing these conditions that allow relearning of emotional responses, our psychotherapists can engage clients with root causes of their addiction.
This is an entirely new paradigm for mental health, where we are moving from palliative care towards permanent cure. We believe this is the biggest change to psychiatry in 100 years.
Read more about our Research and Clinical Trials and How our clinics will operate.
Therapeutic Development Pipeline
Patents
AWKN-P001
AWKN-P001 - is a novel combined therapeutic consisting of racemic ketamine, delivered Intravenously (IV), and specifically designed psycho-social support to treat Severe Alcohol Use Disorder (SAUD). Phase III is currently in planning after hugely successful Phase II a/b results.
(S)-ketamine
Awakn are re-purposing and developing (S)-ketamine, in a proprietary formulation, as a marketed combined therapeutic with psycho-social support to treat Mild and Moderate AUD
MDMA/Zydis
MDMA, an investigational medicinal product (IMP), is an entactogen that acts as a releaser and reuptake inhibitor of serotonin, norepinephrine (NE), and dopamine. MDMA has demonstrated potential efficacy in clinical trials to treat AUD and Post Traumatic Stress Disorder (PTSD), However, challenge exists to the successful development of MDMA as a marketed drug: excessive treatment duration of 6 to 8 hours; variable pharmacokinetics due to gastrointestinal absorption; and first-pass metabolism negatively effecting bioavailability.
Awakn is addressing these challenges by developing a market-ready proprietary formulation and optimized delivery route for MDMA on the Zydis platform.
Sign Up for Newsletter
MAIN OFFICE
Awakn Life Sciences Corp.
301-217 Queen St. W
Toronto, Ontario M5V 0R2
Canada
© 2023 Awakn Life Sciences Corp | Privacy Policy | Disclaimer
